{
  "id": 20609856,
  "title": "GSK Marks Second Lung Cancer Drug Approval This Year",
  "url": "https://urgent.news/2026/11/18/gsk-marks-second-lung-cancer-drug-approval-this-year",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-18T14:51:20.000Z",
  "source": {
    "name": "Benzinga",
    "slug": "benzinga",
    "url": "https://www.benzinga.com/news/fda/26/11/63387226/gsk-marks-second-lung-cancer-drug-approval-this-year"
  },
  "original_language": "en",
  "account": "The Food and Drug Administration (FDA) has granted accelerated approval to GSK Plc.'s (NYSE:GSK) new lung cancer drug, Nelkarmi (neladalkib), for treating locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). This marks the second lung cancer approval for the European drug company in the same year. The FDA's approval is based on the Phase 1/2 ALKOVE-1 trial, which showed significant and lasting results in patients who had previously received one ALK tyrosine kinase inhibitor (TKI) like alectinib or two or more ALK TKIs along with platinum-based chemotherapy in an unresectable locally advanced or metastatic setting.",
  "summary": "On Tuesday, the Food and Drug Administration granted accelerated approval to GSK Plc.’s (NYSE:GSK) Nelkarmi (neladalkib) for locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). The milestone marks the second lung cancer approval this year for the European drug giant. Regulators cleared the kinase inhibitor for patients who previously…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}